[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354740-105":59,"doc-detail-354740-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","car-t-cell-therapy-in-lung-cancer-overcoming-tumor-microenvironment-mediated-barriers","CAR T Cell Therapy in Lung Cancer - Overcoming Tumor Microenvironment-Mediated Barriers","","Chimeric antigen receptor (CAR) T cell therapy delivers strong clinical results in hematological malignancies, yet its effectiveness in lung cancer is limited by the immunosuppressive tumor microenvironment (TME). This review explains how aberrant vasculature and dense stromal extracellular matrix create physical hindrances to CAR T cell infiltration. It further details additional constraints from suppressive myeloid cell networks, inhibitory checkpoint signaling, dysregulated chemokine gradients, and hypoxia-driven metabolic reprogramming that drive dysfunction and exhaustion. Emerging combination regimens, engineered CAR T designs, and microenvironment-modulating platforms are discussed to enhance therapeutic performance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-cell-therapy-in-lung-cancer-overcoming-tumor-microenvironment-mediated-barriers/354740/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-cell-therapy-in-lung-cancer-overcoming-tumor-microenvironment-mediated-barriers/354740.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR T cell therapy less effective in lung cancer than in blood cancers?","Question",{"text":112,"@type":113},"In lung cancer, a highly immunosuppressive tumor microenvironment restricts CAR T cell infiltration, expansion, and function, producing a gap compared with hematologic settings.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What physical barriers in the lung cancer TME impede CAR T cells?",{"text":117,"@type":113},"Aberrant vascular architecture and dense fibrotic extracellular matrix limit immune cell trafficking and restrict CAR T cell entry into tumor tissue.",{"name":119,"@type":110,"acceptedAnswer":120},"Which molecular and cellular mechanisms contribute to CAR T cell dysfunction in lung cancer?",{"text":121,"@type":113},"Myeloid-dominated suppressive networks, immune checkpoint signaling, inhibitory cytokines, dysregulated chemokine gradients, and hypoxia-related metabolic reprogramming collectively create hostile conditions that promote dysfunction and exhaustion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354740,1790169241,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2026; 22(13): 6985-7002. doi: 10.7150/ijbs.131261  \nReview  \nCAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers  \nLu Liu1\\#, Dandan Liang2,3\\#, Cui Wang1, Jian Li4, Jie Tang2, Weimin Li2,3􀀍, Xijie Yu1􀀍  \n1. Laboratory of Endocrinology and Metabolism, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.  \n2. Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.  \n3. State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Chengdu, China.  \n4. Department of Endocrinology and Metabolism, Shandong Second Provincial General Hospital, No. 4, Duanxing West Road, Jinan, Shandong Province, China.  \n\\# These authors contributed equally  \n􀀍 Corresponding authors: Xijie Yu, Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan University, No. 37, Guoxue Xiang, Chengdu 610041, P.R. China, Email: [xijieyu@scu.edu.cn or](xijieyu@scu.edu.cn or) [xijieyu@hotmail.com](xijieyu@hotmail.com); ORCID ID: 0000-0002-3504-7664. Weimin Li, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, P.R. China, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Chengdu 610041, P.R. China, [Email: weimi003@scu.edu.cn](Email: weimi003@scu.edu.cn); ORCID ID: 0000-0003-0985-0311.© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2026.01.11; Accepted: 2026.07.07; Published: 2026.07.22  \nAbstract  \nChimeric antigen receptor (CAR) T cell therapy has achieved remarkable clinical success in hematological malignancies. However, its efficacy in solid tumors such as lung cancer remains constrained by the immunosuppressive tumor microenvironment (TME). Aberrant vascular architecture and dense stroma constitute major physical barriers that hinder CAR T cell infiltration. Additionally, an immunosuppressive cellular network, dominated by myeloid-derived suppressor cells and tumor-associated macrophages, further restricts CAR T cell expansion and function. Moreover, immune checkpoint signaling, inhibitory cytokines, dysregulated chemokine gradients, and metabolic reprogramming under hypoxia collectively create a hostile biochemical and metabolic milieu that drives CAR T cell dysfunction and exhaustion. This review systematically outlines these multifactorial barriers within the lung cancer TME and discusses emerging strategies, including combinatorial approaches, engineered CAR T designs, and microenvironment-modulating platforms, that aim to improve the therapeutic efficacy of CAR T cell therapy in lung cancer.  \nKeywords: lung cancer; CAR T cell therapy; tumor microenvironment; immunotherapy; solid tumors  \n1. Introduction  \nLung cancer remains one of the leading causes of cancer mortality worldwide. In 2022, it accounted for approximately 2.48 million new cases and 1.82 million deaths globally [1] . Targeted therapies and immune checkpoint blockade have reshaped the treatment landscape, and programmed cell death protein 1 (PD- 1) or programmed death-ligand 1 (PD-L1) inhibitors are now incorporated into first-line regimens for advanced non-small cell lung cancer (NSCLC) . However, durable benefit remains limited to a subset of patients. In extensive-stage small cell lung cancer (SCLC), etoposide-platinum chemotherapy yields a median overall survival of about 10 months, and the  \naddition of atezolizumab extends survival to 12.3 months [2] . Against this backdrop, chimeri","cbCaiqLi7n1drLCP","https://ap.wps.com/l/cbCaiqLi7n1drLCP","pdf",11075114,18,"English","# Introduction\n## CAR T cell therapy and clinical context in lung cancer\n# Tumor microenvironment barriers in lung cancer","[{\"question\":\"Why is CAR T cell therapy less effective in lung cancer than in blood cancers?\",\"answer\":\"In lung cancer, a highly immunosuppressive tumor microenvironment restricts CAR T cell infiltration, expansion, and function, producing a gap compared with hematologic settings.\"},{\"question\":\"What physical barriers in the lung cancer TME impede CAR T cells?\",\"answer\":\"Aberrant vascular architecture and dense fibrotic extracellular matrix limit immune cell trafficking and restrict CAR T cell entry into tumor tissue.\"},{\"question\":\"Which molecular and cellular mechanisms contribute to CAR T cell dysfunction in lung cancer?\",\"answer\":\"Myeloid-dominated suppressive networks, immune checkpoint signaling, inhibitory cytokines, dysregulated chemokine gradients, and hypoxia-related metabolic reprogramming collectively create hostile conditions that promote dysfunction and exhaustion.\"}]","CAR T Cell Therapy in Lung Cancer - Overcoming Tumor Microenvironment-Mediated Barriers | PDF",1790113431,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83555271b798089370b70deffb68a5e9.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/349064a4dbda51f862cdfcbbbef5fa49.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04a8f23846c46da246092b38e3251b96.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2f7ac98b43094f3fb0e2a582337ec1c.webp",980,1268]